Companies: 10,795·Total market cap: $144.5T
TriSalus Life Sciences, Inc.

TriSalus Life Sciences, Inc.

TLSINASDAQHealthcare● Active
$3.21
+$0.04(+1.26%)
Market Cap$121691610
P/E Ratio
52W High$7.95
52W Low$2.2
Overview

TriSalus Life Sciences, Inc. (TLSI) PE Ratio — Current & Historical Data

Trailing twelve months (TTM) P/E, forward P/E, PEG, and annual PE history — from market prices and filings.

tlsi · pe ratio · data through Dec 31, 2025

Core PE Ratio Metrics

Trailing 12 months · TTM

The price-to-earnings (P/E) ratio for TriSalus Life Sciences, Inc. (TLSI) measures how much investors pay for each dollar of the company's trailing earnings. TLSI's current PE ratio of N/A is calculated by dividing its stock price of $3.21 by its TTM earnings per share of -$0.53.

N/A
P/E Ratio (TTM)N/A — Company is not profitable (TTM)

Source: FMP · /ratios-ttm · /analyst-estimates · 2025-12-31

Forward P/E
N/A
FY2027 est. EPS $-0.16
Based on 2 analysts
EPS (TTM)
-$0.53
TTM · diluted EPS
PEG Ratio
0.10
Below 1.0 · Growth adjusted
Source: FMP · /ratios-ttm · /ratios annual · /analyst-estimates · /stock-peers · TriSalus Life Sciences, Inc. SEC 10-K & 10-Q filings · US GAAPUpdated: 2026-06-08

PE Ratio History

2020 – 2025 · Annual
PE Ratio (TTM)
EPS (Annual)

▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare (Annual)

PE Ratio vs Peers

Medical - Devices · 6 peers · Annual PE
CompanyMarket CapPE (Annual)vs AvgEPS (TTM)
TriSalus Life Sciences, Inc.
TriSalus Life Sciences, Inc.You
TLSI
$122MN/A-$0.53
Armata Pharmaceuticals, Inc.
Armata Pharmaceuticals, Inc.
ARMP
$278MN/A-$4.80
Anteris Technologies Global Corp.
Anteris Technologies Global Corp.
AVR
$344MN/A-$3.99
Perspective Therapeutics, Inc.
Perspective Therapeutics, Inc.
CATX
$226MN/A-$1.40
LENSAR, Inc.
LENSAR, Inc.
LNSR
$68MN/A-$2.87
MaxCyte, Inc.
MaxCyte, Inc.
MXCT
$123MN/A-$0.42
Nano-X Imaging Ltd.
Nano-X Imaging Ltd.
NNOX
$127MN/A-$1.16

* N/A — Company is not profitable (TTM) · excluded from industry average · ▸ FMP /stock-peers + /ratios?limit=1 · priceToEarningsRatio

Annual PE Ratio History

Showing 6 of 6 years
Fiscal Year EndPE RatioEPS (TTM)YoY ChangePE vs Max
2025-12-31Latest
FY2025
$-0.80
2024-12-31
FY2024
$-1.25
2023-12-31
FY2023
$-2.24
2022-12-31
FY2022
$-1.59
2021-12-31
FY2021
$-0.92
2020-12-31
FY2020
$-1.04

▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare · Zero extra API

About PE Ratio & Methodology

The price-to-earnings (P/E) ratio for TriSalus Life Sciences, Inc. (TLSI) measures how much investors pay for each dollar of the company's trailing earnings. TLSI's current PE ratio of N/A is calculated by dividing its stock price of $3.21 by its TTM earnings per share of -$0.53.

PE Ratio = Stock Price ÷ EPS (TTM)
= $3.21 ÷ -$0.53 = N/A
TTMTrailing Twelve Months — sum of the most recent 4 quarterly EPS figures
Forward PEStock price ÷ analyst consensus EPS estimate for the next fiscal year
PEGPE ÷ earnings growth rate — values below 1.0 suggest growth may justify the premium
Figures tie to SEC 10-K/10-Q and FMP ratio endpoints where noted.

Frequently asked questions

TLSI pe ratio · 6 questions

TLSI's current PE ratio is N/A as of 2026-06-08, based on a stock price of $3.21 and TTM EPS of -$0.53. Data sourced from Financial Modeling Prep via TLSI's SEC 10-K and 10-Q filings.

TLSI PE ratioWhat is TLSI PE ratioCurrent PE ratio of TLSITLSI PE ratio today

Source: FMP · /ratios-ttm · /ratios annual · /analyst-estimates · /stock-peers · TriSalus Life Sciences, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: 2026-06-08